Reviewing Chimerix Inc. (CMRX)’s and Stellar Biotechnologies Inc. (NASDAQ:SBOT)’s results

Chimerix Inc. (NASDAQ:CMRX) and Stellar Biotechnologies Inc. (NASDAQ:SBOT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chimerix Inc. 8.78M 20.41 67.34M -1.43 0.00
Stellar Biotechnologies Inc. N/A 3.13 5.35M -1.75 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Chimerix Inc. and Stellar Biotechnologies Inc.


Table 2 represents Chimerix Inc. (NASDAQ:CMRX) and Stellar Biotechnologies Inc. (NASDAQ:SBOT)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chimerix Inc. -766.97% -37.3% -35.1%
Stellar Biotechnologies Inc. 0.00% -52.6% -49.9%

Risk & Volatility

Chimerix Inc.’s current beta is 1.43 and it happens to be 43.00% more volatile than Standard & Poor’s 500. Stellar Biotechnologies Inc.’s 3.00% more volatile than Standard & Poor’s 500 which is a result of the 1.03 beta.


13.6 and 13.6 are the respective Current Ratio and a Quick Ratio of Chimerix Inc. Its rival Stellar Biotechnologies Inc.’s Current and Quick Ratios are 16 and 15.6 respectively. Stellar Biotechnologies Inc. has a better chance of clearing its pay short and long-term debts than Chimerix Inc.

Analyst Recommendations

In next table is given Chimerix Inc. and Stellar Biotechnologies Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Chimerix Inc. 0 3 1 2.25
Stellar Biotechnologies Inc. 0 0 0 0.00

The downside potential is -0.28% for Chimerix Inc. with consensus target price of $3.5.

Insider & Institutional Ownership

Roughly 80.1% of Chimerix Inc. shares are owned by institutional investors while 9.9% of Stellar Biotechnologies Inc. are owned by institutional investors. Insiders owned roughly 1.3% of Chimerix Inc.’s shares. Competitively, insiders own roughly 0.9% of Stellar Biotechnologies Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Chimerix Inc. 37.83% 39.39% 73.58% 10.84% -20.69% 43.19%
Stellar Biotechnologies Inc. -1.9% -4.63% -8.04% -5.5% -53.39% 13.19%

For the past year Chimerix Inc. has stronger performance than Stellar Biotechnologies Inc.


Chimerix Inc. beats on 7 of the 10 factors Stellar Biotechnologies Inc.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. The company offers its KLH protein under the Stellar KLH brand. Its products include Stellar KLH protein in various grades, formulations, and configurations for preclinical and clinical applications, as well as certain KLH-based in vitro diagnostic kits for preclinical use. The companyÂ’s customers and partners include multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.